CO6270285A2 - Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida - Google Patents
Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamidaInfo
- Publication number
- CO6270285A2 CO6270285A2 CO10054262A CO10054262A CO6270285A2 CO 6270285 A2 CO6270285 A2 CO 6270285A2 CO 10054262 A CO10054262 A CO 10054262A CO 10054262 A CO10054262 A CO 10054262A CO 6270285 A2 CO6270285 A2 CO 6270285A2
- Authority
- CO
- Colombia
- Prior art keywords
- amino
- seh
- compound
- relates
- arilmetilcicloalquilcarboxamida
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/46—Phenazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97915407P | 2007-10-11 | 2007-10-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6270285A2 true CO6270285A2 (es) | 2011-04-20 |
Family
ID=40549589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10054262A CO6270285A2 (es) | 2007-10-11 | 2010-05-06 | Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8173805B2 (enExample) |
| EP (1) | EP2214487B1 (enExample) |
| JP (1) | JP5372943B2 (enExample) |
| KR (1) | KR101546111B1 (enExample) |
| CN (1) | CN101896065B (enExample) |
| AU (1) | AU2008310732B2 (enExample) |
| BR (1) | BRPI0817542A2 (enExample) |
| CA (1) | CA2702265C (enExample) |
| CO (1) | CO6270285A2 (enExample) |
| CR (1) | CR11423A (enExample) |
| CY (1) | CY1114865T1 (enExample) |
| DK (1) | DK2214487T3 (enExample) |
| DO (1) | DOP2010000101A (enExample) |
| EA (1) | EA018414B1 (enExample) |
| ES (1) | ES2445444T3 (enExample) |
| HR (1) | HRP20140105T1 (enExample) |
| IL (1) | IL204889A (enExample) |
| MA (1) | MA31761B1 (enExample) |
| MX (1) | MX2010003942A (enExample) |
| MY (1) | MY157116A (enExample) |
| NZ (1) | NZ584471A (enExample) |
| PL (1) | PL2214487T3 (enExample) |
| PT (1) | PT2214487E (enExample) |
| RS (1) | RS53180B (enExample) |
| SI (1) | SI2214487T1 (enExample) |
| UA (1) | UA107444C2 (enExample) |
| WO (1) | WO2009049157A1 (enExample) |
| ZA (1) | ZA201002465B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008105968A1 (en) | 2006-11-03 | 2008-09-04 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| JP5411867B2 (ja) | 2007-10-11 | 2014-02-12 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびそれらの使用 |
| NZ584471A (en) | 2007-10-11 | 2012-01-12 | Glaxosmithkline Llc | Triazine cyclohexane carboxamide compounds and their use |
| FR2948027A1 (fr) | 2009-07-17 | 2011-01-21 | Merck Sante Sas | Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8809552B2 (en) * | 2011-11-01 | 2014-08-19 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015104422A1 (en) | 2014-01-13 | 2015-07-16 | Basf Se | Dihydrothiophene compounds for controlling invertebrate pests |
| WO2015155129A1 (en) * | 2014-04-07 | 2015-10-15 | Basf Se | Diaminotriazine compound |
| US10308648B2 (en) | 2014-10-16 | 2019-06-04 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| US20210378995A1 (en) * | 2018-10-10 | 2021-12-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction |
| WO2024105225A1 (en) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
| EP4618985A1 (en) | 2022-11-18 | 2025-09-24 | Universitat De Barcelona | Dual inhibitors of sigma-1 receptor and soluble epoxide hydrolase and their use in the treatment of pain |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5420283A (en) * | 1993-08-02 | 1995-05-30 | Pfizer Inc. | Resolution of (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonylmethylamino)-piperidine] amide |
| CA2320730A1 (en) * | 1998-12-23 | 2000-07-06 | Renhua Li | Thrombin or factor xa inhibitors |
| WO2002004448A2 (en) * | 2000-07-07 | 2002-01-17 | Neotherapeutics, Inc. | Methods for treatment of drug-induced peripheral neuropathy and related conditions |
| US6451814B1 (en) * | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
| MX242553B (es) | 2000-10-20 | 2006-12-06 | Eisai Co Ltd | Derivados aromaticos que contienen nitrogeno. |
| US20020091133A1 (en) * | 2000-12-12 | 2002-07-11 | Eve M. Taylor | Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis |
| AP2003002825A0 (en) * | 2000-12-21 | 2003-09-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| MXPA03011681A (es) * | 2001-06-29 | 2004-03-19 | Boehringer Ingelheim Pharma | Uso de inhibidores de epoxido hidrolasa soluble, para tratar enfermedades relacionadas con la enfermedad cardiovascular. |
| US20030055249A1 (en) | 2001-07-17 | 2003-03-20 | Fick David B. | Synthesis and methods of use of pyrimidine analogues and derivatives |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7375222B2 (en) * | 2002-02-05 | 2008-05-20 | Astellas Pharma Inc. | 2,4,6-Triamino-1,3,5-triazine derivative |
| WO2003097050A2 (en) | 2002-05-16 | 2003-11-27 | Pharmacia Corporation | A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases |
| US20050197350A1 (en) * | 2003-03-31 | 2005-09-08 | Taisho Pharmaceutical Co., Ltd. | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| EP1638955A2 (en) * | 2003-07-02 | 2006-03-29 | Vertex Pharmaceuticals Incorporated | Pyrimidines useful as modulators of voltage-gated ion channels |
| US7223759B2 (en) * | 2003-09-15 | 2007-05-29 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds |
| ATE547404T1 (de) * | 2003-09-22 | 2012-03-15 | Msd Kk | Piperidinderivate |
| GB0401269D0 (en) | 2004-01-21 | 2004-02-25 | Astrazeneca Ab | Compounds |
| AU2005289426A1 (en) * | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2006053109A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
| AU2005316599A1 (en) | 2004-12-14 | 2006-06-22 | Vertex Pharmaceuticals Incorporated | Pyrimidine inhibitors of ERK protein kinase and uses therof |
| JP2008540433A (ja) * | 2005-05-06 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性エポキシドヒドロラーゼインヒビター及びその使用方法 |
| CA2622754A1 (en) * | 2005-10-07 | 2007-04-19 | Boehringer Ingelheim International Gmbh | N-substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors |
| US20090099184A1 (en) * | 2006-02-16 | 2009-04-16 | Boehringer Ingelheim International Gmbh | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| AR059826A1 (es) * | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| WO2008105968A1 (en) | 2006-11-03 | 2008-09-04 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| EP2217068A4 (en) | 2007-10-11 | 2011-09-14 | Glaxosmithkline Llc | NOVEL INHIBITORS OF SEH AND THEIR USE |
| JP5411867B2 (ja) * | 2007-10-11 | 2014-02-12 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびそれらの使用 |
| NZ584471A (en) | 2007-10-11 | 2012-01-12 | Glaxosmithkline Llc | Triazine cyclohexane carboxamide compounds and their use |
| WO2009048154A1 (ja) | 2007-10-12 | 2009-04-16 | Nec Corporation | 半導体装置及びその設計方法 |
| WO2009070497A1 (en) | 2007-11-28 | 2009-06-04 | Smithkline Beecham Corporation | SEH AND 11 β-HSD1 INHIBITORS AND THEIR USE |
| WO2009073772A1 (en) | 2007-12-06 | 2009-06-11 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| WO2009097475A1 (en) | 2008-01-30 | 2009-08-06 | Smithkline Beecham Corporation | NOVEL sEH INHIBITORS AND THEIR USE |
| JP2011510998A (ja) | 2008-01-30 | 2011-04-07 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびその使用 |
| WO2009097474A1 (en) | 2008-01-30 | 2009-08-06 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| WO2010011917A1 (en) | 2008-07-25 | 2010-01-28 | Glaxosmithkline Llc | SEH AND 11β-HSD1 DUAL INHIBITORS |
-
2008
- 2008-10-10 NZ NZ584471A patent/NZ584471A/en unknown
- 2008-10-10 WO PCT/US2008/079517 patent/WO2009049157A1/en not_active Ceased
- 2008-10-10 JP JP2010529081A patent/JP5372943B2/ja active Active
- 2008-10-10 EA EA201070442A patent/EA018414B1/ru not_active IP Right Cessation
- 2008-10-10 HR HRP20140105AT patent/HRP20140105T1/hr unknown
- 2008-10-10 BR BRPI0817542-0A2A patent/BRPI0817542A2/pt active Search and Examination
- 2008-10-10 AU AU2008310732A patent/AU2008310732B2/en active Active
- 2008-10-10 EP EP08838314.6A patent/EP2214487B1/en active Active
- 2008-10-10 ES ES08838314.6T patent/ES2445444T3/es active Active
- 2008-10-10 KR KR1020107010233A patent/KR101546111B1/ko active Active
- 2008-10-10 DK DK08838314.6T patent/DK2214487T3/da active
- 2008-10-10 MY MYPI2010001613A patent/MY157116A/en unknown
- 2008-10-10 SI SI200831142T patent/SI2214487T1/sl unknown
- 2008-10-10 PT PT88383146T patent/PT2214487E/pt unknown
- 2008-10-10 US US12/682,073 patent/US8173805B2/en active Active
- 2008-10-10 CN CN200880120430XA patent/CN101896065B/zh active Active
- 2008-10-10 UA UAA201005720A patent/UA107444C2/uk unknown
- 2008-10-10 MX MX2010003942A patent/MX2010003942A/es active IP Right Grant
- 2008-10-10 PL PL08838314T patent/PL2214487T3/pl unknown
- 2008-10-10 CA CA2702265A patent/CA2702265C/en active Active
- 2008-10-10 RS RS20140078A patent/RS53180B/sr unknown
-
2010
- 2010-04-06 IL IL204889A patent/IL204889A/en active IP Right Grant
- 2010-04-08 MA MA32751A patent/MA31761B1/fr unknown
- 2010-04-08 ZA ZA2010/02465A patent/ZA201002465B/en unknown
- 2010-04-09 US US12/757,089 patent/US8212032B2/en active Active
- 2010-04-09 DO DO2010000101A patent/DOP2010000101A/es unknown
- 2010-05-06 CO CO10054262A patent/CO6270285A2/es active IP Right Grant
- 2010-05-11 CR CR11423A patent/CR11423A/es unknown
-
2014
- 2014-02-18 CY CY20141100122T patent/CY1114865T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6270285A2 (es) | Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida | |
| ECSP10010556A (es) | Piridinas y pirazinas como inhibidores de pi3k | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| PE20170247A1 (es) | Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1 | |
| SV2010003598A (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa | |
| ECSP088891A (es) | Derivados bicíclicos como inhibidores de cetp | |
| PA8580301A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| UY30481A1 (es) | Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos. | |
| ECSP088099A (es) | Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas | |
| SG148178A1 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
| UA94129C2 (ru) | Соединения для ингибирования митоза | |
| ATE440834T1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| MX2012004311A (es) | Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes. | |
| DK2368887T3 (da) | 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer | |
| UY30316A1 (es) | Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| MX2009009238A (es) | Nuevos inhibidores de fosfodiesterasa. | |
| EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
| BRPI0716069A2 (pt) | composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio | |
| CR11208A (es) | Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas | |
| DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| NI200700189A (es) | Ciclopropil -(2,3-dimetilbencil)amidos del ácido 7-{4-[2-(2,6-dicloro-4-metilfenoxi)- etoxi]fenil}-3,9- diazabiciclo [3.3.1]non-6-en-6-carboxílico como inhibidores de renina para el tratamiento de la hipertensión. | |
| NO20083738L (no) | Sekundaere aminer som renininhibitorer | |
| ATE540038T1 (de) | Heterocyclen als proteinkinaseinhibitoren | |
| TW200745066A (en) | Novel PTP1B inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |